This is a news story, published by VOA, that relates primarily to Journavx news.
For more Journavx news, you can click here:
more Journavx newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from VOA, you can click here:
more news from VOAOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Vertex Pharmaceuticals. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest opioid medicines news, opioid medications news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
opioid painkillersVOA
•Health
Health
73% Informative
FDA approves Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.
It's the first new pharmaceutical approach to treating pain in more than 20 years .
Studies showed Vertex 's drug provided more relief than a dummy pill but didn't outperform a common opioid-acetaminophen combination pill.
VR Score
79
Informative language
82
Neutral language
57
Article tone
semi-formal
Language
English
Language complexity
63
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links
